肝动脉输注奥沙利铂联合静脉5-氟尿嘧啶和西妥昔单抗一线治疗结直肠肝转移的多中心II期试验
这项多中心单臂II期研究纳入35例不可切除或需复杂肝切除的结直肠肝转移患者,接受肝动脉输注奥沙利铂联合静脉5-氟尿嘧啶、亚叶酸和西妥昔单抗每两周一次治疗。可评估患者客观缓解率为88%(95%CI 71%-96%),中位无进展生存期17.9个月,中位总生存期46.3个月。作者认为该方案高效,应进一步研究。
要点
- 可评估患者客观缓解率为88%(95%CI 71%-96%)。
- 中位无进展生存期17.9个月,中位总生存期46.3个月。
- 66%患者(23/35)接受了根治性手术切除和/或消融。
核心结论
- 肝动脉输注奥沙利铂联合全身5-氟尿嘧啶和西妥昔单抗在不可切除结直肠肝转移一线治疗中似高度有效,应进一步研究。
研究设计与样本
- 多中心、单臂II期研究,纳入35例未接受过转移性疾病化疗、不适合根治性切除或需复杂/大范围肝切除的结直肠肝转移患者,来自8个中心。
主要发现
- 可评估患者(n=32)客观缓解率为88%(95%CI 71%-96%),22例RAS/BRAF野生型可评估患者中为95%(95%CI 70%-100%)。
- 中位随访8.8年(95%CI 8.7-未达到),中位无进展生存期17.9个月(95%CI 15-23),中位总生存期46.3个月(95%CI 40.0-未达到)。
- 35例中23例(66%)接受根治性手术切除和/或消融,其中25例RAS野生型肿瘤患者中22例(79%)接受。
- 肝动脉导管保持通畅者占86%,中位奥沙利铂输注8次(范围1-19)。
- 治疗毒性可控,无毒性死亡。
临床怎么用
- 原文未据此给出推荐,作者认为该方案在不可切除结直肠肝转移一线治疗中似高度有效,应进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy and tolerability of hepatic arterial infusion (HAI) oxaliplatin plus systemic 5-fluorouracil and cetuximab as frontline treatment in patients with colorectal liver metastases (CRLM) are unknown. METHODS: In this multicenter, single-arm phase II study, patients with CRLM not amenable to curative-intent resection or requiring complex/major liver resection, and no prior chemotherapy for metastatic disease, received HAI oxaliplatin and intravenous 5-fluorouracil, leucovorin and cetuximab, every two weeks until disease progression, limiting toxicity or at least 3 months after complete response or curative-intent resection/ablation. The primary endpoint was overall response rate (ORR). RESULTS: 35 patients, mostly with bilateral (89%), multiple CRLM (>4, 86%; >10, 46%) were enrolled in eight centers. The ORR was 88% (95% CI, 71%-96%) among evaluable patients (n = 32), and 95% (95% CI 70-100%) among the 22 wild-type RAS/BRAF evaluable patients. After a median follow-up of 8.8 years (95% CI, 8.7-not reached), median progression-free survival was 17.9 months (95% CI, 15-23) and median overall survival (OS) was 46.3 months (95% CI, 40.0-not reached). 23 of the 35 patients (66%), including 22 (79%) of the 25 patients with wild-type RAS tumor, underwent curative-intent surgical resection and/or ablation of CRLM. HAI catheter remained patent in 86% of patients, allowing for a median of eight oxaliplatin infusions (range, 1-19). Treatment toxicity was manageable, without toxic death. CONCLUSION: HAI oxaliplatin plus systemic 5-fluorouracil and cetuximab appears highly effective in the frontline treatment of patients with unresectable CRLM and should be investigated further.
引用
- Malka D, Verret B, Faron M, et al. Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial. Eur J Cancer. 2023. PMID: 37922632. doi:10.1016/j.ejca.2023.113400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。